Healthtech startup RISA Labs, co-founded in 2024 by Kshitij Jaggi and Kumar Shivang, has raised US $11.1 million in a Series A funding round, marking a major step in its mission to transform oncology workflows using artificial intelligence. The round was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, Ventureforgood’s John Simon and existing investor Binny Bansal, co-founder of Flipkart.

Founded to address critical inefficiencies in cancer care, RISA Labs has developed an AI operating system that orchestrates administrative and clinical workflows including prior authorisation, benefits verification, diagnostics coordination and treatment planning by breaking them into micro tasks managed by intelligent agents. This platform aims to reduce bottlenecks, improve coordination between providers and accelerate treatment decisions for oncology patients.

The funding will enable RISA Labs to scale product development and accelerate deployment with hospitals, cancer care networks, specialty pharmacies and infusion centres across the United States. The company’s solution has shown promise in tackling prior authorisation delays a common source of treatment delays in oncology by automating manual processes that traditionally slow access to care.

With the latest capital infusion, RISA Labs plans to expand customer onboarding, enhance platform capabilities and support wider adoption of its AI-centric workflow automation tools in complex clinical environments. The platform’s ability to automate both administrative and clinical tasks represents a growing trend in applying sophisticated AI to improve efficiency and patient experience in specialised care delivery.